Loading...
•
Sep 30, 2024
Elanco Q3 2024 Earnings Report
Elanco's Q3 2024 financial results were reported, with revenue of $1,030 million and organic constant currency growth of 1%.
Key Takeaways
Elanco Animal Health reported its Q3 2024 financial results, achieving revenue of $1,030 million with 1% organic constant currency growth. The company received U.S. FDA approval for Zenrelia™ and Credelio Quattro™, and tightened its full-year 2024 financial guidance.
Revenue reached $1,030 million, with organic constant currency growth of 1%.
Reported EPS was $0.73, and Adjusted EPS was $0.13.
U.S. FDA approved Zenrelia™ and Credelio Quattro™.
Full-year 2024 revenue guidance tightened to $4,420 to $4,450 million, with 3% organic constant currency growth.
Revenue by Segment
Forward Guidance
Elanco is tightening financial guidance for the full year 2024 and providing guidance for the fourth quarter of 2024.
Positive Outlook
- Revenue between $1.00 billion and $1.03 billion is anticipated for Q4 2024.
- Organic constant currency revenue growth of 1% to 4% is expected in Q4 2024.
- Full year 2024 revenue is projected to be between $4,420 to $4,450 million.
- Full year 2024 organic constant currency growth is expected to be 3%.
- Innovation sales contribution is expected between $420 million to $450 million for the full year.
Challenges Ahead
- Reported net loss is expected to be between $(59) million and $(32) million for Q4 2024.
- The impact of foreign exchange rates on revenue is expected to be a headwind of approximately $5 million in Q4 2024.
- The impact of foreign exchange rates on revenue is now expected to be a headwind of approximately $25 million for full year 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...